Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis

BACKGROUND: Hypomethylating agents (HMAs) are believed to have reliable efficacy in treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Meanwhile, the adverse events of HMAs have become an increasing concern. There is, however, no systematic meta-analysis available to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Chong, Wang, Jia, Li, Ya, Zhao, Huan, Li, Ruibai, Hou, Li, Zhang, Yayue, Tian, Shaodan, Liang, Huan, Wang, Chong, Chen, Xinyi, Wang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112947/
https://www.ncbi.nlm.nih.gov/pubmed/30142779
http://dx.doi.org/10.1097/MD.0000000000011860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112947/
https://www.ncbi.nlm.nih.gov/pubmed/30142779
http://dx.doi.org/10.1097/MD.0000000000011860

Ejemplares similares